cobiprostone

Cobiprostone is a synthetic derivative of prostaglandin E1, structurally related to lubiprostone. It is designed as a chloride channel activator, intended to increase intestinal fluid secretion and promote bowel motility. Cobiprostone has been investigated primarily for the treatment of gastrointestinal disorders such as chronic constipation and non-erosive reflux disease (NERD). Its mechanism of action involves activation of chloride channels on the apical membrane of gastrointestinal epithelial cells, leading to increased secretion of chloride-rich fluid into the intestinal lumen, which softens stool and facilitates bowel movements. Cobiprostone was developed by Sucampo Pharmaceuticals (now part of Mallinckrodt), but it has not reached regulatory approval in major markets.

Brand names

AmitizaLubigutLubilaxLubowel

Other names

rubiprostol芦比前列酮